Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Novo Nordisk Says FDA Approves To Update Victoza Product Label

RELATED NEWS
Trade NVO now with 

Novo Nordisk A/S (NVO: Quote) said Friday that the US Food and Drug Administration has approved to update the product label for Victoza to include data showing superior blood sugar control and weight reduction when compared to Januvia. The update also includes data showing the safety and efficacy of adding basal insulin to Victoza and metformin for the treatment of adults with type 2 diabetes.

The label update is based on data from two large, randomized, open-label studies in adults with type 2 diabetes.

"The data from these studies further demonstrate the strong clinical profile and the value of Victoza in the treatment of type 2 diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

Click here to receive FREE breaking news email alerts for Novo Nordisk A/S and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.